To analyze the prognostic value of microsatellite instability (MSI) in a population-based study of FIGO stage 1-4 endometrial endometrioid adenocarcinomas.
Introduction
Endometrial adenocarcinoma is the most frequent gynecologic cancer. The disease-related death rate in FIGO stage 2-4 range from 20-80% and greater while in the "favorable" early stage FIGO 1, the death rate is only 5 to 10% [3, 31] . The latter has been stable for decades [41] . This wide range of disease-related death rate prompts the search for more reliable prognostic indicators both to enable more accurate triaging of patients concerning treatment modalities, and to gain better mechanistic insights into the disease.
In early FIGO stage 1 cancers, histologic type, grade and myometrium invasion depth (MI) are often used to determine individual therapy, but their prognostic accuracy and reproducibility are not always optimal [3, 41, 43] . Increased understanding of the molecular biology in endometrial carcinogenesis has revealed several promising prognostic and predictive biomarkers, such as microsatellite instability (MSI), a characteristic finding in cancers deficient in DNA mis-match repair (MMR), seen in 9-45% of sporadic endometrial cancers (Table 1) [1, [4] [5] [6] [7] 10, 12, 16, 17, 19, 25, 26, 28, 29, 32, 33, 42, 44] . In contrast to Hereditary NonPolyposis Colorectal Cancer (HNPCC) or Lynch syndrome, which is an autosomal dominant condition involving germline MMR gene mutation, sporadic en- [15] . Mixing types I and II endometrial cancers in fact may seriously blur the analysis. Not surprisingly, the results of different studies published thus far on MSI vary greatly. A large multicenter study consisting of 446 endometrioid (type I) endometrial cancers only and found that MSI has no prognostic value [44] . However, in spite of the large numbers of patients, it also mixed all stages which may have seriously biased the conclusions for FIGO stage 1 type I cancers. Another shortcoming was that the MSI markers used were less sensitive than the recently described ones assessed by the pentaplex polymerase chain reaction assay [8, 9, 42] . Another recent study of interest investigated early stage radiation-treated endometrioid tumors only with the same MSI markers as ours, and concluded on a negative prognostic value for MSI-H patients [6] .
In the present study we investigated whether MSI assessed with the pentaplex polymerase chain reaction assay containing five sensitive mononucleotide repeats has prognostic value in a population-based study of consecutive endometrioid endometrial cancer patients.
Materials and methods
The current MSI study is part of a project on endometrial carcinogenesis, approved prior to the initiation of the study by the Regional Ethics Committee and Norwegian Data Inspection.
Cases
The cohort used in this study was population-based from Rogaland-south, a county in South West Norway covering approximately 350,000 inhabitants. From January 1, 1989 through December 31, 2004, 363 cases of endometrial cancer were diagnosed at the Stavanger University Hospital, the only hospital in the region. From this group the following cases were excluded: lack of follow-up (7 cases), no adequate histologic material available for additional studies (39 cases) or no diagnostic evidence of invasive adenocarcinoma on histologic material reviewed by two gynecologic pathologists (EG, JB) (13 cases), leaving 304 patients in the study. In agreement with other large studies, none of the patients in our series received preoperative hormonal or chemotherapy. Surgery was performed shortly after the pathology diagnosis was rendered. Patients with FIGO stage 1A, 1B or 1C, well and moderately differentiated cancers, received only surgical treatment consisting of total abdominal hysterectomy with bilateral salpingo-oophorectomy. Adjuvant postoperative radiotherapy (RT) was administered to all patients with FIGO stage 1C poorly differentiated cancers, and all patients with FIGO stage 2 cancers. Patients with FIGO stages 3 and 4 cancers were treated post-operatively with radiation or chemotherapy or both. All patients were followed at 3-monthly intervals. Standard surveillance included physical examination and cytologic smears for at least 2 years after initial treatment. Assessments with additional cytologic and imaging studies or directed biopsies were performed as clinically indicated at the discretion of the treating physician. Recurrent disease was histologically confirmed.
The sampling and tissue processing procedures were standardized as follows. Tissue slices of approximately 4 mm in thickness were routinely fixed in 4% buffered formaldehyde, dehydrated, paraffin embedded, sections cut at 4-µm and haematoxylin-eosinsaffran (HES) stained. Histologic grade and type, cervical involvement and myometrium invasion of all cases were re-reviewed by two of us (EG, JB) and histologic grade and type of the FIGO 1 cases was re-reviewed by one more independent gynecologic pathologist (AM, EG, JB) using the WHO 2003 criteria. Staging was performed according to the original FIGO staging system [23] . In the few cases where there was disagreement between the reviewing pathologists whether a case was type 1, type 2, neuroendocrine cancer or sarcoma, additional immunohistochemical studies including p16, p53, chromogranin, synaptophysin, pan-CK, ER, E-cadherin and desmin were performed to clarify the diagnosis. After the rereview the 304 cases were distributed as follows: FIGO stage 1, 248 cases (82%); FIGO stage 2, 28 cases (9%); FIGO stage 3, 18 cases (6%) and FIGO stage 4, 10 cases (3%) (similar distribution to the one seen in other studies). There were 30 non-endometrioid endometrial cancers. One more case was excluded because the sections and blocks were not available at the time of review by one of us (AM), leaving 273 endometrioid endometrial cancers and 224 FIGO 1 cancers for analysis. 62 cases were excluded from MSI analysis (too little material/bad quality material, cancer tissue cut through, n = 45 + 17) leaving 211 cases for MSI analysis.
Microsatellite analysis
Microsatellite analysis was performed on DNA isolated from archived, paraffin-embedded tissue blocks using tissue from the invasive front of each tumor (avoiding areas with extensive necrosis or normal tissue), using the QIAamp DNA Mini Kit (Qiagen™, Hilden, Germany) following the manufacturer's protocol for DNA-isolation. MSI analysis was performed using five microsatellite markers (BAT26, BAT25, NR21, NR24, NR27) known to be quasimonomorphic, with low risk for polymorphisms in the Caucasian population, as previously described [8, 9, 37, 40] . The difference in MSI markers used by us, and in the large endometrioid endometrial cancer study by Zighelboim et al. [44] was considerable: only BAT25 and BAT26 were the same. Markers NR21, NR24 and NR27 are sensitive for MSI detection as described elsewhere [8, 9, 40] . The selected markers showed a high sensitivity for MSI detection without the need for matching with patient's normal DNA. The primer sequences are listed in Table 2 and primers were labelled with either FAM or HEX fluorescent dyes. PCR-amplification was performed under standard conditions. The reactions were incubated at 95 • C for five minutes followed by 35 cycles of 95 • C, 56 • C and 72 • C for one minute each. The product length was analysed using a sequencer (GeneAnalyzer™ 3130XL, Applied Biosystems) with the GeneMap™ software. MSI in any marker was visualized as changes in the product length (Fig. 1) . Instability in 40% ( 2 of 5) of the markers was classified as high-frequency microsatellite instability (MSI-H), in 1 of 5 markers as low-frequency (MSI-L), and in no markers as microsatellite stable (MSS). In line with other studies, MSI-L were grouped together with MSS cases for most analyses.
Statistical analysis
The quality of the database input data was controlled by checking descriptive statistics and cross tables for all patients, to trace unlikely values or combinations. We analyzed the following endpoints: alive with local or distant recurrence (n = 6), and dead of endometrial cancer (n = 28). As recurrence and dead of endometrial cancer gave the same results, the recurrence cases and dead of endometrial cancer cases were grouped together and further described. Patients with death from other non-endometrial cancer related 250 Notes: F denotes forward primer sequence; R denotes reverse primer sequence. The fluorescent markers used were FAM for BAT26, NR24 and NR27, and HEX for BAT25 and NR21. causes, or patients lost to follow-up were censored at the last known follow-up date as alive, no evidence of disease (ANED). Analyses were performed by SPSS version 15 (SPSS, Chicago, IL, USA). For age (a continuous variable) we used the median, tertiles and quartiles as thresholds, or the threshold with the objectively best sensitivity and specificity assessed by Receiver Operating Curve (ROC) analysis (MedCalc Software, Mariakerke, Belgium), for details of the ROC technique [22] . The two methods always pointed to the same threshold which was used in further analyzes. The chi-square test was used to determine the relationship between MSI-status and the clinico-pathological risk factors. Univariate analysis was performed using the Kaplan-Meier method, and differences in survival were estimated by the Breslow and log-rank tests. Hazard ratios (HR) and 95% confidence intervals (95% CI) were calculated for each feature. Multivariate survival analysis (Cox model) was used to assess the independent prognostic value of the different features.
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Results
In the 273 FIGO stage 1-4 cases of endometrioid endometrial adenocarcinoma studied, the median age was 66 (range 32-94) years. With median follow-up of 61 months (range 1-209), 34 (12.5%) patients developed metastases. Table 3 shows the correlation between MSI and the other variables. MSI-H is associated with high grade (grades 2 and 3), whereas grade 1 cancers more often are MSS or MSI-L. sion. MSS and MSI-L cancers (84% of all cases) had a good prognosis, whereas MSI-H cancers (16%) were associated with a worse survival, as shown by the survival curve (Fig. 2) . The 5-and 10-year recurrencefree survival rates were 98% and 95%, respectively, in the MSS/MSI-L vs. 85% and 73%, respectively, in the MSI-H cancer patients. In the multivariate analysis, MSI had a prognostic value only in FIGO stage 1 cancers.
Discussion
In this population-based endometrioid endometrial cancer study MSI showed a prognostic value but only for FIGO stage 1 cancers. MSI is an objective marker and many studies found MSI to be a valuable and promising prognostic indicator in other types of cancer, especially gastric and colonic cancer. For endometrial cancer the results have been conflicting with as many studies showing prognostic value as not. A large multicenter study found that MSI-L/MSS vs. MSI-H was not of prognostic value [44] . We could confirm this for all FIGO stages analysed together. However, in the 2007 study no subgroup analysis on FIGO stage 1 cases was performed.
Another recent study of interest analysed early stage endometrioid cancers with the same panel of markers as we did (these markers have been proven to be more reliable than the ones used in other series [8, 9, 42] ). The study concluded on a negative prognostic value of MSI-H cases, but in contrast to our study all of their cases were radiation-treated [6] . MSI-L and MSI-H were found in 11% and 16% of the cancers analyzed (totalling 27%). Of 17 previous studies on MSI in endometrial cancer, the prevalence of MSI widely varied from 9% to 45% [1, 4, 5, 7, 10, 12, 16, 17, 19, 25, 26, 28, 29, 32, 33, 42, 44] (Table 1 ). The table also illustrates the enormous variation in the numbers of patients, stages, histotypes and molecular techniques used in the different studies. MSI is also found in atypical hyperplasia [18] , indicating that MSI is an early event in a subset of endometrial cancer. Late stage endometrial cancers are more likely to have accumulated many genetic changes, this is supported by our findings of an increasing MSI-H rate in FIGO 2 cancers of 27% and in FIGO 3 cancers 33%. For FIGO 4 there where lacking data for 4 out of 10 cases, and only 1 case were MSI-H ( types I and II cancers which follow different pathways is likely to further blur the evaluation of the prognostic value of MSI. We conclude therefore that one must be careful when attempting to draw any conclusions from these studies for the most frequent endometrial cancer: FIGO stage 1 endometrioid endometrial cancer. Interestingly, the behaviour of endometrioid endometrial cancer according to MSI seems the opposite of that in colonic and gastric cancers, where MSI-H tumors have a better prognosis [34, 36] . Chemotherapy is widely used in these cancers, contrasting the habits in early stage endometrioid cancer. This raised the question whether MSI-H cancers may be especially sensitive for chemotherapy. If so, FIGO stage 1 endometrioid cancer patients with MSI-H may benefit from adjuvant chemotherapy. Chemotherapy data is unfortunately incomplete for our patient population.
The sharp increase of endometrial cancer incidence during the last few decades in the western world and increasingly in many young patients of childbearing age, raises the important point of fertility-sparing and ovary-saving surgery. Patients with obesity, diabetes or cardiovascular disease amongst others, also would benefit from less aggressive surgery such as vaginal hysterectomy and no lymphadenectomy. This of course requires reliable preoperative identification of low-and high risk patients. MSS/MSI-L status is shown here to be an adequate marker to identify endometrioid FIGO stage 1 cancers with a very low risk, while MSI-H identifies the small subgroup of aggressive cancers. This may be used to indicate radical surgery, radiotherapy and early start of postoperative adjuvant chemotherapy as suggested above.
The molecular causes and consequences of MSI in sporadic endometrial carcinomas have been less well studied. In sporadic colorectal cancers, MSI is associated with somatic hypermethylation of the promoter of the mismatch repair gene hMLH1 [11, 35] as is the case in the great majority of sporadic endometrial carcinomas [14, 21] . Furthermore, RASSF1A promoter is also frequently methylated in endometrial carcinoma and significantly associated with MSI [20, 30] . APC promoter hypermethylation is correlated with MSI in endometrioid endometrial carcinomas [27] . Moreover, high frequency promoter methylation of P16, MGMT [13] , and RARb2 [2] , were found in endometrial carcinoma and lack of CDH13 promoter hypermethylation was prognostic [39] .
Since promoter hypermethylation of certain genes appears to be an early and frequent event in endometrial carcinogenesis, this raises the question of what are the molecular interactions between a tendency for promoter hypermethylation and other genetic changes in FIGO stage 1 endometrial endometrioid adenocarcinoma cases. Type I cancers often show K-ras mutations which are correlated with MSI [24] . We recently found that decreased P21 and survivin overexpression were prognostic [38] . Therefore, what is the prognostic value of combinations of promoter methylation, MSI and genetic changes in FIGO stage 1 endometrial endometrioid adenocarcinoma cases?
Our population-based endometrioid FIGO stage 1 endometrial cancer study on MSI is one of the largest with long and complete long follow up. We conclude that in FIGO stage 1 endometrial endometrioid adenocarcinoma cases, MSI assessed with highly sensitive pentaplex polymerase chain reaction has independent prognostic value.
